One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Emerging causes and risk factors of heart failure: amyloidosis, myocarditis, immune checkpoint inhibitors, air pollution, and visceral adipose tissue
Filippo Crea
doi : 10.1093/eurheartj/ehab214
European Heart Journal, Volume 42, Issue 16, 21 April 2021, Pages 1533–1537
Music of the cosmos and the heart
Lina Tonia, Alexandros Stefanidis, Nick Mparmpatzas, Bogdan A Popescu
doi : 10.1093/eurheartj/ehaa539
European Heart Journal, Volume 42, Issue 16, 21 April 2021, Pages 1538–1540
Hospital Ram?n y Cajal, Madrid, Spain
Rocio Hinojar, MD PhD, José Luis Zamorano, MD PhD
doi : 10.1093/eurheartj/ehaa999
European Heart Journal, Volume 42, Issue 16, 21 April 2021, Pages 1540–1541
The Year in Cardiovascular Medicine 2020: Valvular Heart Disease
Mark Nicholls
doi : 10.1093/eurheartj/ehaa1024
European Heart Journal, Volume 42, Issue 16, 21 April 2021, Pages 1542–1543
Cryoblation as first-line treatment of new-onset atrial fibrillation?
Leonarda Galiuto, Massimo Volpe
doi : 10.1093/eurheartj/ehab161
European Heart Journal, Volume 42, Issue 16, 21 April 2021, Pages 1543–1544,
European position paper on the management of patients with patent foramen ovale. Part II - Decompression sickness, migraine, arterial deoxygenation syndromes and select high-risk clinical conditions
Christian Pristipino, MD, Peter Germonpré, MD, Danilo Toni, MD, Horst Sievert, MD, Bernhard Meier, MD
doi : 10.1093/eurheartj/ehaa1070
European Heart Journal, Volume 42, Issue 16, 21 April 2021, Pages 1545–1553
Patent foramen ovale (PFO) is implicated in the pathogenesis of a number of medical conditions but to date only one official position paper related to left circulation thromboembolism has been published. This interdisciplinary paper, prepared with the involvement of eight European scientific societies, reviews the available evidence and proposes a rationale for decision making for other PFO-related clinical conditions. In order to guarantee a strict evidence-based process, we used a modified grading of recommendations, assessment, development, and evaluation (GRADE) methodology. A critical qualitative and quantitative evaluation of diagnostic and therapeutic procedures was performed, including assessment of the risk/benefit ratio. The level of evidence and the strength of the position statements were weighed and graded according to predefined scales. Despite being based on limited and observational or low-certainty randomised data, a number of position statements were made to frame PFO management in different clinical settings, along with suggestions for new research avenues. This interdisciplinary position paper, recognising the low or very low certainty of existing evidence, provides the first approach to several PFO-related clinical scenarios beyond left circulation thromboembolism and strongly stresses the need for fresh high-quality evidence on these topics.
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases
Pablo Garcia-Pavia, Claudio Rapezzi, Yehuda Adler, Michael Arad, Cristina Basso
doi : 10.1093/eurheartj/ehab072
European Heart Journal, Volume 42, Issue 16, 21 April 2021, Pages 1554–1568
Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the hereditary forms or as a consequence of acquired conditions. Thanks to advances in imaging techniques and the possibility of achieving a non-invasive diagnosis, we now know that cardiac amyloidosis is a more frequent disease than traditionally considered. In this position paper the Working Group on Myocardial and Pericardial Disease proposes an invasive and non-invasive definition of cardiac amyloidosis, addresses clinical scenarios and situations to suspect the condition and proposes a diagnostic algorithm to aid diagnosis. Furthermore, we also review how to monitor and treat cardiac amyloidosis, in an attempt to bridge the gap between the latest advances in the field and clinical practice.
Temporal changes in total and hippocampal brain volume and cognitive function in patients with chronic heart failure—the COGNITION.MATTERS-HF cohort study
Anna Frey, Gy?rgy A Homola, Carsten Henneges, Larissa Mühlbauer, Roxane Sell
doi : 10.1093/eurheartj/ehab003
European Heart Journal, Volume 42, Issue 16, 21 April 2021, Pages 1569–1578
We quantified the concurring dynamics affecting total and hippocampal brain volume and cognitive function in patients with chronic heart failure (HF) over a period of three years.
Heart failure, cognition, and brain damage
Arno Villringer, Ulrich Laufs
doi : 10.1093/eurheartj/ehab061
European Heart Journal, Volume 42, Issue 16, 21 April 2021, Pages 1579–1581
Joint exposure to various ambient air pollutants and incident heart failure: a prospective analysis in UK Biobank
Mengying Wang, Tao Zhou, Yongze Song, Xiang Li, Hao Ma
doi : 10.1093/eurheartj/ehaa1031
European Heart Journal, Volume 42, Issue 16, 21 April 2021, Pages 1582–1591
Little is known about the relation between the long-term joint exposure to various ambient air pollutants and the incidence of heart failure (HF). We aimed to assess the joint association of various air pollutants with HF risk and examine the modification effect of the genetic susceptibility.
Air pollution and flooding in the lungs: modern insights into ancient problems
Sanjay Rajagopalan, Robert D Brook, Sadeer Al-Kindi
doi : 10.1093/eurheartj/ehaa1105
European Heart Journal, Volume 42, Issue 16, 21 April 2021, Pages 1592–1594
Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction
Hidemi Sorimachi, Masaru Obokata, Naoki Takahashi, Yogesh N V Reddy, Christopher C Jain
doi : 10.1093/eurheartj/ehaa823
European Heart Journal, Volume 42, Issue 16, 21 April 2021, Pages 1595–1605
Central obesity is a major risk factor for heart failure with preserved ejection fraction (HFpEF), particularly in women, but the mechanisms remain unclear. We hypothesized that sex-specific differences in visceral adipose tissue (VAT) content would differentially relate to haemodynamic severity of HFpEF in women and men.
Fighting HFpEF in women: taking aim at belly fat
Coenraad Withaar, Laura M G Meems, Rudolf A de Boer
doi : 10.1093/eurheartj/ehaa952
European Heart Journal, Volume 42, Issue 16, 21 April 2021, Pages 1606–1608
Myocarditis-associated necrotizing coronary vasculitis: incidence, cause, and outcome
Andrea Frustaci, Maria Alfarano, Romina Verardo, Chiara Agrati, Rita Casetti
doi : 10.1093/eurheartj/ehaa973
European Heart Journal, Volume 42, Issue 16, 21 April 2021, Pages 1609–1617
Necrotizing coronary vasculitis (NCV) is a rare entity usually associated to myocarditis which incidence, cause, and response to therapy is unreported.
Myocarditis: endomyocardial biopsy and circulating anti-heart autoantibodies are key to diagnosis and personalized etiology-directed treatment
Alida L P Caforio
doi : 10.1093/eurheartj/ehab024
European Heart Journal, Volume 42, Issue 16, 21 April 2021, Pages 1618–1620
The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study
Maria D’Souza, Dorte Nielsen, Inge Marie Svane, Kasper Iversen, Peter Vibe Rasmussen
doi : 10.1093/eurheartj/ehaa884
European Heart Journal, Volume 42, Issue 16, 21 April 2021, Pages 1621–1631
The study aimed to estimate the risk of cardiac events in immune checkpoint inhibitor (ICI)-treated patients with lung cancer or malignant melanoma.
Are we underestimating the potential for cardiotoxicity related to immune checkpoint inhibitors?
Matthias Totzeck, Esther Lutgens, Tomas G Neilan
doi : 10.1093/eurheartj/ehaa959
European Heart Journal, Volume 42, Issue 16, 21 April 2021, Pages 1632–1635
Immune check point inhibitors are associated with a spectrum of cardiac events in patients with cancer
Maria D’Souza, Inge Marie Svane, Gunnar Gislason, Morten Schou
doi : 10.1093/eurheartj/ehab066
European Heart Journal, Volume 42, Issue 16, 21 April 2021, Page 1636
Cardiac events associated with immune checkpoint inhibitor therapy: the devil is in the detail
Markus S Anker, Andrew J S Coats, Stefan D Anker
doi : 10.1093/eurheartj/ehab063
European Heart Journal, Volume 42, Issue 16, 21 April 2021, Page 1637
A novel deletion of the dystrophin gene in a patient without muscle-related symptoms
Tomoya Sato, Masahiro Wakita, Masaaki Matsushima, Takuma Sato
doi : 10.1093/eurheartj/ehaa928
European Heart Journal, Volume 42, Issue 16, 21 April 2021, Page 1638
Delayed diffuse inflammatory myocardial damage in a child with a history of systemic inflammatory syndrome related to COVID-19
Mohammad Mahdavi, Golnaz Houshmand, Hamidreza Pouraliakbar, Golnar Mortaz Hejri
doi : 10.1093/eurheartj/ehaa1028
European Heart Journal, Volume 42, Issue 16, 21 April 2021, Page 1639
